Sarepta Therapeutics Inc. - notizie pubblicate 202 - letture 1.810
SAREPTA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
SAREPTA THERAPEUTICS INC.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer sarepta therapeutics inc. published th ...
SAREPTA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
SAREPTA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
SAREPTA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
SAREPTA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
SAREPTA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
SAREPTA THERAPEUTICS INC.
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer sarepta therapeutics inc. published th ...
SAREPTA THERAPEUTICS INC.
Submission of Matters to a Vote of Security Holders Form 8 K
Item 5.02. departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. on june 7, 2024, the b ...
SAREPTA THERAPEUTICS INC.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4) 5/31/24 cambridge, mass.--(businesswire)--may 31, 2024-- sarepta therapeutics, inc. (nasdaq:sr ...
SAREPTA THERAPEUTICS INC.
P.413-251 Seo et al. In situ biodistribution & localization of SRP-9003 in LGMD2ER4 Mice
In situ biodistribution and localization of bidridistrogene xeboparvovec (srp-9003) in lgmd2e/r4 mice young seo, stephen fasul, chrissy hopkins, akansha pradhan, jasmine wu, alex h ...
SAREPTA THERAPEUTICS INC.
P.1412 Mendell et al. Safety and Efficacy of Del Mox v. Pbo in DMD Phase 3 EMBARK
1412 safety and efficacy of delandistrogene moxeparvovec versus placebo in duchenne muscular dystrophy: phase 3 embark primary results jr mendell,1,2* f muntoni,3 cm mcdonald,4 em ...
SAREPTA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
SAREPTA THERAPEUTICS INC.
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer sarepta therapeutics ...
SAREPTA THERAPEUTICS INC.
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer sarepta therapeutics ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti